Persistent fetal circulation, endothelin-1, pulmonary hypertension, hypoxia, animal model, bronchopulmonary dysplasia Disorders such as persistent pulmonary hypertension of the newborn (PPHN) and bronchopulmonary dysplasia (BPD) each affect more than 10,000 newborn infants every year in the U.S. alone, resulting in considerable mortality and morbidity. A common feature of these disorders is abnormal remodeling of the pulmonary blood vessels after birth and elevated pulmonary arterial pressures. Certain congenital heart diseases with markedly increased pulmonary blood flow also have abnormal pulmonary vasculature and high pulmonary blood pressures. Pulmonary arterial pressures are high in the fetus, and normally decrease at birth with lung inflation and oxygenation. Chronic hypoxemia just before birth or in the neonatal period may lead to abnormal thickening of the pulmonary arteries and pulmonary hypertension.
Disorders such as persistent pulmonary hypertension of the newborn (PPHN) and bronchopulmonary dysplasia (BPD) each affect more than 10,000 newborn infants every year in the U.S. alone, resulting in considerable mortality and morbidity. A common feature of these disorders is abnormal remodeling of the pulmonary blood vessels after birth and elevated pulmonary arterial pressures. Certain congenital heart diseases with markedly increased pulmonary blood flow also have abnormal pulmonary vasculature and high pulmonary blood pressures. Pulmonary arterial pressures are high in the fetus, and normally decrease at birth with lung inflation and oxygenation. Chronic hypoxemia just before birth or in the neonatal period may lead to abnormal thickening of the pulmonary arteries and pulmonary hypertension.
A recent study published in Pediatric Research [1] showed that blockade of the endothelin-A receptor was able to prevent and partially reverse hypoxia-induced pulmonary arterial remodeling in a newborn animal model. Endothelin-1 (ET-1) is a 21-amino-acid polypeptide that mediates vasoconstriction through the ET-A receptor located primarily on vascular smooth muscle cells and vasodilation through ET-B receptors located on endothelial cells. It has been previously shown that ET-1 levels are increased in newborn infants with PPHN, and are correlated with disease severity and decline with resolution of disease [2, 3] .
A previous study [4] showed that blockade of the ET-A receptor was able to reduce acute hypoxiainduced pulmonary hypertension in piglets, which generated the hypothesis that ET-A blockade may also be effective in preventing and reversing the effects of longer-term hypoxia on the pulmonary vasculature. To test this hypothesis, a newborn mouse model of hypoxia-induced pulmonary arterial remodeling was developed by exposure of C57BL/6 mice from birth to 2 weeks of age to hypoxia (12% oxygen) in a controlled environment chamber, along with their dams. The newborn mice were injected daily with either vehicle (cottonseed oil) or a selective ET-A antagonist (BQ-610) from either birth (the prevention study) or from 6 days of age (the reversal study). The effects of hypoxia on the pulmonary vasculature were evaluated by morphometry of the small pulmonary arteries, and by evaluation of right ventricular hypertrophy (an index of pulmonary hypertension, which causes hypertrophy of the right ventricle). It was observed that chronic hypoxia exposure led to thickening of small pulmonary arteries (<100 μm diameter) and right ventricular hypertrophy. ET-A blockade was able to prevent the thickening of small pulmonary arteries and right ventricular hypertrophy when given from birth, and significantly reduced the arterial thickening when given from 6 days of age. These results demonstrate that ET-1 acting via ET-A receptors is a mediator of chronic hypoxia-mediated pulmonary arterial remodeling, and suggests that ET-A blockers may have therapeutic relevance in disorders such as PPHN or BPD.
Selective ET-A blockers are already known as promising therapeutic agents for adults with pulmonary hypertension [5, 6] . The animal study described here indicates that such agents may also be suitable for the treatment of sick neonates with pulmonary hypertension and abnormal pulmonary vascular remodeling. However, several hurdles remain before ET-A antagonists enter the therapeutic armamentarium of neonatologists. ET-A antagonists are essentially untested in human neonates to date, and side effects such as hepatic toxicity are a concern in neonates who normally have impairment of some hepatic functions in the postnatal period. Initially, pilot trials of ET-A antagonists in neonates and older infants are required, evaluating safety and physiologic efficacy. Subsequently, larger randomized clinical trials are required to demonstrate efficacy of these agents on outcomes such as survival, need for extracorporeal membrane oxygenation (ECMO), and long-term morbidity in infants with established pulmonary hypertension. It is possible that effects of ET-A antagonists may be synergistic with the benefits of inhaled nitric oxide and other established therapies for neonatal pulmonary hypertension, and may improve clinical outcomes for critically ill neonates.
